drugset
drugset / Trial / NCT06750341

Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol

NCT06750341 ↗

Phase 2 Not yet recruiting 156 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy, safety, pharmacodynamics and immunogenicity of QLC7401 subcutaneous administration in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C elevated on optimized lipid-lowering therapy.

Timeline

Start
2025-02
Primary completion
2026-06
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject QLC7401 Small interfering RNA (siRNA) 100 mg Subcutaneous
Subject QLC7401 Small interfering RNA (siRNA) 300 mg Subcutaneous
Subject QLC7401 Small interfering RNA (siRNA) 500 mg Subcutaneous

Indications

hyperlipoproteinemia